Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722852 · ClinicalTrials.gov registry record · Phase 3
Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee
A Phase 3 study, sponsored by IDEA.
- Completed
- Registry status
- Phase 3
- Development phase
- 555
- Enrollment target
NCT00722852 is a Phase 3 study that has completed, run by IDEA. The registered enrollment target is 555 participants.
The verdict
NCT00722852, a Phase 3 study, has completed, sponsored by IDEA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 555 participants
- Enrollment target
Study Summary
The purpose of this study is to provide replicated evidence of safety and efficacy of 100 mg ketoprofen in Diractin®.
Interventions
- DRUG Placebo
- DRUG ketoprofen in Diractin®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00722852
The ClinicalTrials.gov registry entry for NCT00722852 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 555 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is IDEA, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00722852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00722852 about?
NCT00722852 is a clinical study titled "Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee". The purpose of this study is to provide replicated evidence of safety and efficacy of 100 mg ketoprofen in Diractin®.
What is the current status of trial NCT00722852?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 555 participants. The study started on 2008-06. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00722852?
The interventions under investigation include: Placebo (DRUG), ketoprofen in Diractin® (DRUG).
Who is sponsoring clinical trial NCT00722852?
This trial is sponsored by IDEA, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.